» Articles » PMID: 25225838

Myositis Registries and Biorepositories: Powerful Tools to Advance Clinical, Epidemiologic and Pathogenic Research

Overview
Specialty Rheumatology
Date 2014 Sep 17
PMID 25225838
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Clinical registries and biorepositories have proven extremely useful in many studies of diseases, especially rare diseases. Given their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndromes, have benefited from individual researchers' collections of cohorts of patients. Major efforts are being made to establish large registries and biorepositories that will allow many additional studies to be performed that were not possible before. Here, we describe the registries developed by investigators and patient support groups that are currently available for collaborative research purposes.

Recent Findings: We have identified 46 myositis research registries, including many with biorepositories, which have been developed for a wide variety of purposes and have resulted in great advances in understanding the range of phenotypes, clinical presentations, risk factors, pathogenic mechanisms, outcome assessment, therapeutic responses, and prognoses. These are now available for collaborative use to undertake additional studies. Two myositis patient registries have been developed for research, and myositis patient support groups maintain demographic registries with large numbers of patients available to be contacted for potential research participation.

Summary: Investigator-initiated myositis research registries and biorepositories have proven extremely useful in understanding many aspects of these rare and diverse autoimmune diseases. These registries and biorepositories, in addition to those developed by myositis patient support groups, deserve continued support to maintain the momentum in this field as they offer major opportunities to improve understanding of the pathogenesis and treatment of these diseases in cost-effective ways.

Citing Articles

Long Term Outcomes in Idiopathic Inflammatory Myositis: An Observational Epidemiologic Study over 15 Years.

Janardana R, Kn S, Bhat V, Balakrishnan D, Raj J, Pinto B Mediterr J Rheumatol. 2024; 34(4):513-524.

PMID: 38282927 PMC: 10815524. DOI: 10.31138/mjr.280823.lto.


Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry.

Neely J, Ardalan K, Huber A, Kim S Pediatr Rheumatol Online J. 2022; 20(1):50.

PMID: 35854378 PMC: 9295519. DOI: 10.1186/s12969-022-00709-3.


B Cells as a Therapeutic Target in Paediatric Rheumatic Disease.

Wilkinson M, Rosser E Front Immunol. 2019; 10:214.

PMID: 30837988 PMC: 6382733. DOI: 10.3389/fimmu.2019.00214.


Risk factors and disease mechanisms in myositis.

Miller F, Lamb J, Schmidt J, Nagaraju K Nat Rev Rheumatol. 2018; 14(5):255-268.

PMID: 29674613 PMC: 6745704. DOI: 10.1038/nrrheum.2018.48.


Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.

McCann L, Pilkington C, Huber A, Ravelli A, Appelbe D, Kirkham J Ann Rheum Dis. 2017; 77(2):241-250.

PMID: 29084729 PMC: 5816738. DOI: 10.1136/annrheumdis-2017-212141.


References
1.
Oddis C, Reed A, Aggarwal R, Rider L, Ascherman D, Levesque M . Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2012; 65(2):314-24. PMC: 3558563. DOI: 10.1002/art.37754. View

2.
Mastaglia F, Needham M, Scott A, James I, Zilko P, Day T . Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord. 2009; 19(11):763-5. DOI: 10.1016/j.nmd.2009.07.015. View

3.
Huber A, Mamyrova G, Lachenbruch P, Lee J, Katz J, Targoff I . Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2013; 66(5):732-40. PMC: 4646219. DOI: 10.1002/acr.22212. View

4.
Sanner H, Sjaastad I, Flato B . Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford). 2014; 53(9):1578-85. DOI: 10.1093/rheumatology/keu146. View

5.
Mathiesen P, Orngreen M, Vissing J, Andersen L, Herlin T, Nielsen S . Aerobic fitness after JDM--a long-term follow-up study. Rheumatology (Oxford). 2012; 52(2):287-95. DOI: 10.1093/rheumatology/kes232. View